文献速递抗栓抗凝管理特殊人群用药

儿科医院两种依诺肝素给药与监测方案的回顾性比较

Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

该研究回顾性比较了儿科患者两种依诺肝素治疗剂量方案的有效性与安全性。标准方案按年龄给予1.5或1 mg/kg并在首剂后监测抗Xa,高剂量方案按年龄给予1.1–1.7 mg/kg并在第二剂后监测。高剂量组总体剂量调整次数中位数更低但无统计学差异,3–11月龄亚组调整次数显著减少。

要点

  • 高剂量方案在3–11月龄亚组中显著减少达到目标抗Xa所需的剂量调整次数。
  • 总体两组剂量调整次数中位数差异无统计学意义(p=0.17)。
  • 高剂量策略未显著增加抗Xa水平超目标的风险。

核心结论

  • 儿科患者起始更高剂量依诺肝素可能比标准剂量减少剂量调整次数。
  • 3–11月龄高剂量亚组显示出获益。
  • 高剂量策略在所有组中安全,未导致超目标水平统计学显著增加。

研究设计与样本

  • 回顾性研究,比较两种依诺肝素给药与监测方案。
  • 标准剂量组n=87,高剂量组n=132。

主要发现

  • 达到目标抗Xa所需剂量调整次数中位数:标准组1(IQR 0-1.5),高剂量组0(IQR 0-1),p=0.17。
  • 3–11月龄亚组剂量调整次数中位数从2(IQR 1-3.25)降至0(IQR 0-1),p<0.01。
  • 其他年龄亚组未见差异。
  • 抗Xa水平超目标患者比例两组无统计学差异。

关键数值与推荐

  • 标准方案:<3月龄1.5 mg/kg/剂,≥3月龄1 mg/kg/剂,首剂后监测抗Xa。
  • 高剂量方案:<3月龄1.7 mg/kg/剂,3–11月龄1.5 mg/kg/剂,1–4岁1.2 mg/kg/剂,5–17岁1.1 mg/kg/剂,第二剂后监测抗Xa。

临床怎么用

  • 对3–11月龄儿科患者起始依诺肝素可考虑高剂量方案以减少剂量调整。
  • 高剂量方案需在第二剂后监测抗Xa水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The study analyzes the effectiveness and safety of a higher than standard enoxaparin dosing protocol implemented for pediatric patients requiring initiation of therapeutic anticoagulation. METHODS: A retrospective review of 2 enoxaparin dosing and monitoring protocols was performed. The standard protocol used 1.5 mg/kg/dose (in patients <3 months of age) and 1 mg/kg/dose (in patients ≥3 months of age) with anti-Xa monitoring following the first dose. The high-dose protocol was implemented at 1.7 mg/kg/dose (in patients <3 months of age), 1.5 mg/kg/dose (in patients 3 through 11 months of age), 1.2 mg/kg/dose (in patients 1 through 4 years of age), and 1.1 mg/kg/dose (in patients 5 through 17 years of age), with anti-Xa monitoring after the second dose. Primary outcomes were number of dosing changes prior to and time to first target anti-Xa level. Secondary outcomes included percentage of patients with anti-Xa levels above target level. RESULTS: The median number of dose changes required to achieve a target anti-Xa level was 1 (interquartile range [IQR], 0-1.5) and 0 (IQR, 0-1) for the standard-dose (n = 87) and high-dose groups (n = 132) (p = 0.17), respectively. The median number of dose adjustments to achieve target anti-Xa levels in the 3 through 11 months of age subgroup declined from 2 (IQR, 1-3.25) to 0 (IQR, 0-1) in the standard- versus high-dose groups, respectively (p < 0.01). No difference was seen in other age subgroups. Patients with above-target levels did not differ statistically between groups. CONCLUSION: Initiating enoxaparin at higher doses in pediatric patients may result in fewer dosing changes than standard dosing. Benefit was demonstrated for the 3-11 months of age high-dose subgroup. Across all groups, the high-dose strategy was safe and did not result in a statistically significant increase in above-target levels.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Wolsey A, Wilcox RA, Olson JA, et al. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital. Am J Health Syst Pharm. 2019. PMID: 31361813. doi:10.1093/ajhp/zxz055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。